EA003129B1 - Замещенные трициклические соединения - Google Patents

Замещенные трициклические соединения Download PDF

Info

Publication number
EA003129B1
EA003129B1 EA199900304A EA199900304A EA003129B1 EA 003129 B1 EA003129 B1 EA 003129B1 EA 199900304 A EA199900304 A EA 199900304A EA 199900304 A EA199900304 A EA 199900304A EA 003129 B1 EA003129 B1 EA 003129B1
Authority
EA
Eurasian Patent Office
Prior art keywords
arthritis
acid
compound
benzyl
mmol
Prior art date
Application number
EA199900304A
Other languages
English (en)
Russian (ru)
Other versions
EA199900304A2 (ru
EA199900304A3 (ru
Inventor
Николас Джеймс Бах
Жоли Анн Бастиан
Дуглас Вейд Бейт
Майкл Дин Кинник
Майкл Джон Мартинелли
Эдвард Дэвид Михелик
Джон Майкл мл. Морин
Дэниел Джон Солл
Джейсон Скотт Сойер
Эдвард С.Р. Смит
Тулио Суарес
Кьюпинг Ванг
Томас Майкл Вильсон
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199900304A2 publication Critical patent/EA199900304A2/ru
Publication of EA199900304A3 publication Critical patent/EA199900304A3/ru
Publication of EA003129B1 publication Critical patent/EA003129B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
EA199900304A 1998-04-17 1999-04-16 Замещенные трициклические соединения EA003129B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6216598A 1998-04-17 1998-04-17

Publications (3)

Publication Number Publication Date
EA199900304A2 EA199900304A2 (ru) 1999-10-28
EA199900304A3 EA199900304A3 (ru) 2000-04-24
EA003129B1 true EA003129B1 (ru) 2003-02-27

Family

ID=22040624

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900304A EA003129B1 (ru) 1998-04-17 1999-04-16 Замещенные трициклические соединения

Country Status (27)

Country Link
EP (2) EP0950661B1 (enExample)
JP (1) JP4435325B2 (enExample)
KR (1) KR19990083234A (enExample)
CN (1) CN1235968A (enExample)
AR (1) AR018185A1 (enExample)
AT (2) ATE254128T1 (enExample)
AU (1) AU757454B2 (enExample)
BR (1) BR9901275A (enExample)
CA (1) CA2269256A1 (enExample)
CO (1) CO5080728A1 (enExample)
CZ (1) CZ137199A3 (enExample)
DE (2) DE69912670T2 (enExample)
EA (1) EA003129B1 (enExample)
ES (2) ES2210979T3 (enExample)
HU (1) HUP9901219A1 (enExample)
ID (1) ID23219A (enExample)
IL (1) IL129484A0 (enExample)
NO (1) NO991823L (enExample)
NZ (1) NZ335252A (enExample)
PE (1) PE20000472A1 (enExample)
PL (1) PL332564A1 (enExample)
SG (1) SG106035A1 (enExample)
SV (1) SV1999000052A (enExample)
TR (1) TR199900842A2 (enExample)
TW (1) TW555760B (enExample)
YU (1) YU19099A (enExample)
ZA (1) ZA992773B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2596823C2 (ru) * 2011-04-14 2016-09-10 Актелион Фармасьютиклз Лтд ПРОИЗВОДНЫЕ 7-(ГЕТЕРОАРИЛ-АМИНО)-6,7,8,9-ТЕТРАГИДРОПИРИДО[1,2-a]ИНДОЛ-УКСУСНОЙ КИСЛОТЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА ПРОСТАГЛАНДИНА D2

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
AU2001244635A1 (en) * 2000-03-30 2001-10-15 Yamanouchi Pharmaceutical Co..Ltd. Hydrazide derivatives
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
ES2264708T3 (es) * 2000-12-18 2007-01-16 Eli Lilly And Company Derivados tetraciclicos como inhibidores de la spla2.
DE60218155D1 (de) 2001-03-28 2007-03-29 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
JP2005527466A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプトＢインドール誘導体
JP2005527464A (ja) * 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体
US6992100B2 (en) 2001-12-06 2006-01-31 Eli Lilly And Company sPLA2 inhibitors
BRPI0517955A (pt) 2004-11-01 2008-10-21 Wyeth Corp indolizinas substituìdas e derivados como agentes de snc
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
SG11201405328SA (en) 2012-03-16 2014-11-27 Vitae Pharmaceuticals Inc Liver x receptor modulators
ES2607113T3 (es) 2012-03-16 2017-03-29 Vitae Pharmaceuticals, Inc. Moduladores de los receptores X del hígado

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
US6645976B1 (en) * 1994-07-21 2003-11-11 Eli Lilly And Company Indolizine SPLA2inhibitors
DE69614232T2 (de) * 1995-12-13 2002-01-10 Eli Lilly And Co., Indianapolis Naphthyl-Acetamide als sPLA2-Inhibitoren
KR20000049210A (ko) * 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
AU9664198A (en) * 1997-09-26 1999-04-23 Eli Lilly And Company Method for the treatment of cystic fibrosis
JP2001522884A (ja) * 1997-11-14 2001-11-20 イーライ・リリー・アンド・カンパニー アルツハイマー病の処置方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2596823C2 (ru) * 2011-04-14 2016-09-10 Актелион Фармасьютиклз Лтд ПРОИЗВОДНЫЕ 7-(ГЕТЕРОАРИЛ-АМИНО)-6,7,8,9-ТЕТРАГИДРОПИРИДО[1,2-a]ИНДОЛ-УКСУСНОЙ КИСЛОТЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА ПРОСТАГЛАНДИНА D2

Also Published As

Publication number Publication date
EP1156050B1 (en) 2004-02-18
SG106035A1 (en) 2004-09-30
EP1156050A3 (en) 2001-11-28
NO991823D0 (no) 1999-04-16
EP0950661B1 (en) 2003-11-12
HU9901219D0 (en) 1999-06-28
EP0950661A1 (en) 1999-10-20
ID23219A (id) 2000-03-30
DE69912670D1 (de) 2003-12-18
EA199900304A2 (ru) 1999-10-28
AU2381899A (en) 1999-10-28
JP4435325B2 (ja) 2010-03-17
ZA992773B (en) 2002-07-16
YU19099A (sh) 2001-09-28
CO5080728A1 (es) 2001-09-25
TW555760B (en) 2003-10-01
KR19990083234A (ko) 1999-11-25
HUP9901219A1 (hu) 2000-08-28
AU757454B2 (en) 2003-02-20
CN1235968A (zh) 1999-11-24
BR9901275A (pt) 2000-05-02
ES2213668T3 (es) 2004-09-01
IL129484A0 (en) 2000-02-29
EP1156050A2 (en) 2001-11-21
NZ335252A (en) 2000-11-24
EA199900304A3 (ru) 2000-04-24
ES2210979T3 (es) 2004-07-01
PE20000472A1 (es) 2000-06-02
DE69914951D1 (de) 2004-03-25
CA2269256A1 (en) 1999-10-17
AR018185A1 (es) 2001-10-31
PL332564A1 (en) 1999-10-25
ATE254128T1 (de) 2003-11-15
JPH11322745A (ja) 1999-11-24
DE69912670T2 (de) 2004-08-12
CZ137199A3 (cs) 1999-11-17
ATE259818T1 (de) 2004-03-15
SV1999000052A (es) 2000-03-14
DE69914951T2 (de) 2004-12-23
NO991823L (no) 1999-10-18
TR199900842A2 (xx) 2000-09-21

Similar Documents

Publication Publication Date Title
US6177440B1 (en) Substituted tricyclics
EP0839806B1 (en) Substituted tricyclics
AU753436B2 (en) Substituted tricyclics
JP2001503055A5 (enExample)
EP1156050B1 (en) Substituted tricyclics useful in sPLA2 induced diseases
US6713645B1 (en) Substituted tricyclics
US6448284B1 (en) Substituted tricyclics
US6933313B2 (en) Substituted carbazoles as inhibitors of sPLA2
HK1025091A (en) Substituted tricyclics useful in spla2 induced diseases
MXPA99003588A (en) Triciclic composites substitui
US20040063967A1 (en) Novel spla2 inhibitors
HK1010546A (en) Substituted tricyclics
HK1024911A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
HK1024912A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
HUP9903545A2 (hu) Helyettesített triciklusos vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
MXPA99003587A (es) Compuestos triciclicos substituidos

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU